Pilot study of p62 DNA vaccine in dogs with mammary tumors
Metrics: PDF 942 views | HTML 751 views | ?
Vladimir Gabai1,*, Franco M. Venanzi2,*, Elena Bagashova3, Oksana Rud3, Francesca Mariotti2, Cecilia Vullo2, Giuseppe Catone2, Michael Y. Sherman4, Antonio Concetti2, Andrey Chursov1, Anastasia Latanova1,5, Vita Shcherbinina1,5 , Victor Shifrin1,* and Alexander Shneider1,5
1 CureLab Oncology Inc, Needham MA, USA
2 School of Biosciences and Veterinary Medicine University of Camerino, Camerino (MC) Italy
3 Center of Modern Veterinary Medicine, Kiev, Ukraine
4 Department Biochemistry, Boston University School of Medicine, Boston MA, USA
5 CL Oncology Moscow, Russia
* joint 1st authorship
Victor Shifrin, email:
Alexander Shneider, email:
Keywords: cancer immunotherapy, vaccine, breast carcinoma, neoadjuvant, p62, canine
Received: September 03, 2014 Accepted: September 24, 2014 Published: September 25, 2014
Our previous data demonstrated profound anti-tumor and anti-metastatic effects of p62 (sqstm1) DNA vaccine in rodents with various types of transplantable tumors. Testing anti-cancer medicine in dogs as an intermediary step of translational research program provides two major benefits. First, clinical data collected in target animals is required for FDA/USDA approval as a veterinary anti-cancer drug or vaccine. It is noteworthy that the veterinary community is in need of novel medicine for the prevention and treatment of canine and feline cancers. The second more important benefit of testing anti-cancer vaccines in dogs is that spontaneous tumors in dogs may provide invaluable information for human trials. Here, we evaluated the effect(s) of p62 DNA vaccine on mammary tumors of dogs. We found that p62 DNA vaccine administered i.m. decreased or stabilized growth of locally advanced lesions in absence of its overall toxic effects. The observed antitumor activity was associated with lymphocyte infiltration and tumor encapsulation via fibrotic reaction. This data justifies both human clinical trials and veterinary application of p62 DNA vaccine.
Primary Contact _
Franco M. Venanzi
Michael Y. Sherman
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.